AEON AEON Biopharma Forecast, Technical & Fundamental Analysis
AEON Biopharma Inc is a biopharmaceutical company focused on the development of ABP-450 (prabotulinumtoxinA), a biosimilar to Botox (onabotulinumtoxinA), for therapeutic indications... Show more
AEON is expected to report earnings to fall 77.43% to -64 cents per share on August 18
Q2'26
Est.
$-0.65
Q4'25
Missed
by $2.64
Q3'25
Missed
by $0.07
Q2'25
Missed
by $0.29
Q1'25
Beat
by $2.57
The last earnings report on March 30 showed earnings per share of -288 cents, missing the estimate of -23 cents. With 7.12M shares outstanding, the current market capitalization sits at 12.94M.
A.I.dvisor tells us that AEON and GERN have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that AEON and GERN's prices will move in lockstep.
AEON's RSI Oscillator recovers from oversold territory
The RSI Indicator for AEON moved out of oversold territory on July 31, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 36 similar instances when the indicator left oversold territory. In of the 36 cases the stock moved higher. This puts the odds of a move higher at .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 54 cases where AEON's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for AEON just turned positive on July 30, 2026. Looking at past instances where AEON's MACD turned positive, the stock continued to rise in of 47 cases over the following month. The odds of a continued upward trend are .
Following a +2 3-day Advance, the price is estimated to grow further. Considering data from situations where AEON advanced for three days, in of 193 cases, the price rose further within the following month. The odds of a continued upward trend are .
AEON may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on July 09, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on AEON as a result. In of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AEON declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for AEON entered a downward trend on July 31, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (19.620). P/E Ratio (0.332) is within average values for comparable stocks, (38.277). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.532). Dividend Yield (0.000) settles around the average of (0.020) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (420.906).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. AEON’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AEON’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
